Oruka Therapeutics, Inc. ORKA R2K
Healthcare · Biotechnology · United States
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
READ MORE ›$58.53
+434.03% 1Y
Market & Price
Market Cap
$3.53B
Current Price
$58.53
High / Low (52W)
$76.39 / $10.90
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$9.63
Price to Book
6.08
P/S
-
EV/EBITDA
-23.60
Dividend Yield
-
Profitability & Returns
ROCE
-22.28%
ROE
-27.31%
ROA
-18.92%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.48
EPS (TTM)
$-1.93
Balance Sheet & Liquidity
Debt/Equity
0.37
Quick Ratio
23.38
Current Ratio
23.76
Debt
$1.81M
Total Assets
$488.62M
Current Assets
$343.86M
Working Capital
$328.48M
Ownership
Promoter Holding
1.29%
Chg in Prom Hold
-
FII / Inst Holding
87.90%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$3.15B
Total Revenue (TTM)
-
EBITDA
$-133.29M
Free Cash Flow
$-56.13M
Operating Cash Flow
$-90.92M
Shares Outstanding
60.31M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Oruka Therapeutics, Inc. R2K | 58.53 | - | $3.53B | - | -22.28% | -27.31% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.09M | 28.43M | 34.10M | 34.43M | 36.43M |
| Operating Income | -2.82M | -3.67M | -3.94M | -4.71M | -4.38M | -5.56M | -4.47M | - | -2.77M | -2.16M | -1.66M | - | -1.78M | -1.51M | -1.25M | - | -1.34M | -1.31M | -1.99M | - | -4.10M | -4.84M | -4.72M | - | -3.28M | -3.22M | -2.55M | - | -1.80M | -1.97M | -1.94M | - | -2.48M | -21.49M | - | -25.09M | -28.43M | -34.10M | -34.43M | -36.43M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.07M | -24.55M | -30.26M | -29.55M | -36.39M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 504.00K | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.00M | -24.57M | -30.28M | -29.58M | -31.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.81M | -3.65M | -3.89M | -4.66M | -4.34M | -5.52M | -4.43M | -4.20M | -2.73M | -2.12M | -1.59M | -1.49M | -1.66M | -1.44M | -1.16M | -1.23M | -1.32M | -1.30M | -1.99M | -5.12M | -4.10M | -4.83M | -4.71M | -5.68M | -3.27M | -3.15M | -2.33M | -1.17M | -1.35M | -1.48M | -1.42M | -1.09M | -2.01M | -22.24M | - | -21.00M | -24.57M | -30.28M | -29.58M | -31.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.34 | -0.33 | - | -0.23 | -0.22 | -0.16 | - | -0.09 | -0.10 | -0.10 | - | -0.14 | -6.96 | -1.46 | -0.40 | -0.46 | -0.55 | - | -0.48 |
| R&D Expense | 1.72M | 2.59M | 2.91M | 3.72M | 3.25M | 4.51M | 3.49M | - | 1.72M | 1.15M | 740.00K | - | 662.00K | 440.00K | 347.00K | - | 365.00K | 372.00K | 1.05M | - | 2.88M | 3.58M | 3.44M | - | 2.18M | 1.49M | 1.02M | - | 390.00K | 254.00K | 322.00K | - | 165.00K | 18.67M | 25.69M | 19.93M | 24.09M | 28.99M | - | 29.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 122.05M |
| Operating Income | - | - | - | - | - | - | -9.18M | -7.36M | -4.32M | -6.94M | -9.69M | -11.46M | -16.61M | -18.71M | -8.12M | -5.81M | -9.77M | -19.34M | -10.60M | -7.30M | -88.12M | -122.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -511.00K | -1.46M | -5.24M | -13.99M | -19.43M | -9.14M | -8.42M | -5.36M | -4.32M | -6.94M | -9.69M | -11.45M | -16.44M | -18.49M | -7.93M | -5.48M | -9.74M | -19.32M | -9.93M | -5.34M | -83.72M | -105.43M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.39 | -0.69 | -0.37 | -3.87 | -1.85 |
| R&D Expense | - | - | - | - | - | - | 3.11M | 2.31M | 1.09M | 2.93M | 5.62M | 7.06M | 12.35M | 14.08M | 4.24M | 1.83M | 4.99M | 13.83M | 4.75M | 1.01M | 75.06M | 100.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Feb 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | 8.16M | 6.50M | 3.21M | 17.08M | 16.13M | 39.57M | 24.63M | 12.37M | 6.83M | 8.54M | 50.43M | 54.92M | 43.09M | 37.86M | 1.00K | 396.02M | 488.62M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 376.87M | 343.86M |
| Cash & Equivalents | - | - | - | - | - | - | 7.76M | 7.03M | 5.94M | 2.92M | 16.76M | 15.35M | 38.80M | 7.40M | 8.70M | 6.61M | 8.36M | 49.07M | 53.36M | 42.45M | 37.43M | - | 61.58M | 46.94M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
| Total Liabilities | - | - | - | - | - | - | - | 1.39M | 770.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.44M | 2.09M | 793.00K | 926.00K | 3.91M | 3.88M | 1.41M | 841.00K | - | 16.73M | 19.62M |
| Current Liabilities | - | - | - | - | - | - | - | 1.19M | 754.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.40M | 2.07M | 793.00K | 926.00K | 3.50M | 3.50M | 1.13M | 637.00K | - | 13.04M | 15.37M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 968.00K | 1.93M |
| Total Equity | -115.00K | -619.00K | -678.00K | -5.74M | -19.69M | -38.18M | 7.41M | 6.77M | 5.73M | 2.91M | 15.58M | 14.74M | 38.07M | 22.19M | 10.28M | 6.03M | 7.61M | 46.52M | 51.04M | 41.67M | 37.02M | 1.00K | 379.29M | 469.00M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.44M | 48.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.32M | -6.96M | -4.08M | -5.29M | - | - | - | -17.47M | -8.24M | -4.80M | -7.72M | -18.76M | -10.91M | -5.01M | -57.84M | -88.21M |
| Investing Cash Flow | 265.00K | 2.01M | - | -32.00K | - | - | - | 12.93M | 3.05M | -4.00K | -19.00K | -43.00K | -2.00K | 0 | -330.13M | -96.75M |
| Financing Cash Flow | 7.32M | 3.87M | 1.05M | 19.16M | - | - | - | 5.85M | 3.10M | 6.56M | 48.45M | 23.09M | 0 | 0 | 449.54M | 170.31M |
| Capital Expenditure | -4.00K | -19.00K | - | -32.00K | -19.00K | -11.00K | -12.00K | -3.00K | -4.00K | -4.00K | -19.00K | -43.00K | -2.00K | -0 | -189.00K | -209.00K |
| Free Cash Flow | -8.33M | -6.98M | - | -5.32M | - | - | - | -17.48M | -8.25M | -4.80M | -7.74M | -18.80M | -10.91M | -5.01M | -58.03M | -88.42M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 82.6% | 215.2% | 91.2% | 71.1% | 50.9% | -123.3% | -124.4% | -93.6% | -148.6% | -44.5% | -65.7% | -30.1% | -74.1% | -180.0% | -131.5% | -72.0% | -20.9% | -37.9% | -23.8% | -14.4% | -22.1% | -22.5% |
| ROCE % | - | - | - | - | - | - | -131.7% | -128.1% | -148.6% | -44.5% | -65.7% | -30.1% | -74.7% | -181.8% | -134.6% | -76.4% | -20.8% | -37.6% | -25.3% | -19.6% | -23.0% | -25.8% |
Shareholding Pattern
Insiders
1.29%
Institutions
87.90%
Public Float
89.05%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.32% | 7.43M | $434.96M |
| 2 | Venrock Adviser, LLC | 6.88% | 4.15M | $242.81M |
| 3 | Fairmount Funds Management LLC | 6.14% | 3.71M | $216.87M |
| 4 | Blackrock Inc. | 5.85% | 3.53M | $206.44M |
| 5 | Viking Global Investors, L.P. | 4.42% | 2.67M | $156.08M |
| 6 | Paradigm Biocapital Advisors LP | 3.85% | 2.32M | $135.81M |
| 7 | RTW Investments LP | 3.41% | 2.06M | $120.46M |
| 8 | Deep Track Capital, Lp | 3.37% | 2.03M | $119.06M |
| 9 | Vanguard Capital Management LLC | 3.08% | 1.86M | $108.84M |
| 10 | State Street Corporation | 2.68% | 1.61M | $94.44M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORKA
No recent headlines available.